# Kawasaki disease vs. MIS-C in a child with congenital coronary artery anomaly: a case report

**Authors:** Oksana Boyarchuk, Marta-Viktoriia Zaleshchuk, Roksolana Zaremba, Oksana Chubata, Hanna Morkovkina

PMC · DOI: 10.3389/fped.2026.1768080 · Frontiers in Pediatrics · 2026-02-17

## TL;DR

A 7-year-old boy with overlapping features of Kawasaki disease and MIS-C developed coronary aneurysms, highlighting the challenges in diagnosing and treating these conditions.

## Contribution

This case report presents a rare scenario where a congenital coronary artery anomaly complicates the diagnosis of KD and MIS-C.

## Key findings

- The patient exhibited features of both incomplete Kawasaki disease and MIS-C after SARS-CoV-2 exposure.
- Coronary artery aneurysms developed despite a rapid response to glucocorticoid therapy.
- A congenital coronary artery anomaly was identified, complicating the interpretation of coronary findings.

## Abstract

Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C), associated with SARS-CoV-2 infection share overlapping clinical and laboratory features, making differential diagnosis particularly challenging during the COVID-19 pandemic. Accurate distinction is essential due to differences in pathophysiology, management strategies, and cardiovascular outcomes. We report the case of a 7-year-old boy presenting with prolonged fever, mucocutaneous manifestations, arthritis, and elevated inflammatory markers following SARS-CoV-2 exposure. The clinical course demonstrated features compatible with both incomplete Kawasaki disease and MIS-C. Laboratory findings and cardiac biomarkers showed a mixed profile, while echocardiography and coronary imaging revealed the development of coronary artery aneurysms. Notably, a complex congenital coronary artery anomaly was incidentally identified during coronary evaluation. Although such anomalies are not considered independent risk factors for coronary aneurysm formation, their presence may complicate the interpretation of coronary findings in the setting of systemic inflammation. The patient showed a rapid and sustained clinical response to systemic glucocorticoid therapy without intravenous immunoglobulin administration; however, coronary artery aneurysms subsequently developed. This case highlights the diagnostic and therapeutic challenges at the interface of KD and MIS-C and underscores the importance of an integrated, individualized approach that incorporates clinical evolution, laboratory data, and detailed coronary assessment.

## Linked entities

- **Diseases:** Kawasaki disease (MONDO:0012727), MIS-C (MONDO:0100163)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, CLTA (clathrin light chain A) [NCBI Gene 1211] {aka LCA}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}
- **Diseases:** aneurysm (MESH:D000783), dyspnea (MESH:D004417), valvular involvement (MESH:D006349), inflammatory vascular disease (MESH:D014652), abdominal pain (MESH:D015746), coronary arteritis (MESH:D001167), hyperinflammatory condition (MESH:D020763), gastrointestinal symptoms (MESH:D012817), inflammation (MESH:D007249), shock (MESH:D012769), congenital anomaly (MESH:D000013), hip pain (MESH:D010146), Hyperinflammation syndromes (MESH:D013577), coronary abnormalities (MESH:D003327), psoriasis (MESH:D011565), Fever (MESH:D005334), cheilitis (MESH:D002613), pericardial effusion (MESH:D010490), vomiting (MESH:D014839), neck pain (MESH:D019547), lymphadenitis (MESH:D008199), cervical lymphadenopathy (MESH:D002575), left ventricular systolic dysfunction (MESH:D018487), rash (MESH:D005076), lymphadenopathy (MESH:D008206), febrile (MESH:D000071072), nausea (MESH:D009325), hip joint rotation (MESH:D025981), hyperemia (MESH:D006940), overweight (MESH:D050177), adenoviral infection (MESH:D007239), aneurysmal dilatation (MESH:D002311), Cardiovascular involvement (MESH:D002318), coagulopathy (MESH:D001778), Still's disease (MESH:D016706), COVID-19 (MESH:D000086382), juvenile idiopathic arthritis (MESH:D001171), coronary anomaly (MESH:D003330), vascular injury (MESH:D057772), joint pain (MESH:D018771), involvement (MESH:C564676), leukocytosis (MESH:D007964), arthritis (MESH:D001168), MIS-C (MESH:C000705967), rhinorrhea (MESH:D012818), pharyngeal erythema (MESH:D010612), neutrophilia (MESH:C563010), conjunctivitis (MESH:D003231), immune dysregulation (OMIM:614878), aneurysmal dilatation of the RCA (MESH:D003323), lip dryness (MESH:D014987), mucosal changes (MESH:D052016), sinus tachycardia (MESH:D013616), thrombocytosis (MESH:D013922), cardiac decompensation (MESH:D006333), KD (MESH:D009080), cardiac involvement (MESH:D006331), systemic vasculitis (MESH:D056647), systemic hyperinflammation (MESH:D015619), CAA (MESH:D003324)
- **Chemicals:** triglycerides (MESH:D014280), acetylsalicylic acid (MESH:D001241), MP (MESH:D008775), DEX (MESH:D003915), dexamethasone (MESH:D003907), antiplatelet (-), prednisolone (MESH:D011239), steroid (MESH:D013256)
- **Species:** Avihepevirus magniiecur (species) [taxon 1678144], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953561/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953561/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953561/full.md

---
Source: https://tomesphere.com/paper/PMC12953561